North of the Ordinary: Oncology matchmaking event in Berlin
17.10.2025, 17:30 - 18:30 GMT+01:00
Seminar
Join us for a matchmaking event designed to bring together global industry leaders and top Norwegian oncology clinicians.
Registration for the event is now closed. For any questions or further information, please see the contacts listed below.
This is your opportunity to explore new partnerships, present your pipeline and connect with experts who share your vision of advancing precision medicine through clinical research in a public healthcare system.
Norway is charting a bold path forward in clinical research. Backed by the Norwegian Ministry of Health’s national strategy and supported by NorTrials – the single-entry point for international companies – we’re redefining how clinical trials are done: efficient, collaborative and driven by real patient benefit. Now, we invite you to be part of it.
Target group for participation: Industry representatives looking to engage in individual (1:1) meetings with clinicians specializing in a defined therapeutic field, including:
- Gastrointestinal cancer
- Urological cancer
- Pulmonary cancer
- Breast cancer
- Melanoma
- Head and neck cancer
Please indicate which therapy area you want to discuss in the registration form.
Transport Information
Transport will be provided between the Embassy at the Felleshus – Nordische Botschaften and the Ambassador’s Residence, where the reception will take place. Guests are kindly asked to gather at the Felleshus at the designated time for departure.
Signe Øien Fretland
Head of NorTrials coordinating unit; Cand. Pharm.
Maria C. Lundstad Aulie
Investment Manager | Greater Oslo region
Health and life science
Martin Nietz
Senior Advisor | D-A-CH
Important conditions
Companies must adhere to standards for responsible business conduct, including Environmental, Social, and Governance (ESG) criteria.
Participants are expected to operate in accordance with the UN Guiding Principles on Business and Human Rights and the OECD Guidelines for Multinational Enterprises on Responsible Business Conduct. This entails conducting business responsibly, respecting human rights, ensuring decent working conditions, safeguarding environmental considerations, and actively preventing corruption.
Companies must carry out their own due diligence assessments (risk assessments) to identify, prevent, and mitigate potential adverse impacts.